101
Participants
Start Date
October 27, 2020
Primary Completion Date
February 20, 2023
Study Completion Date
June 28, 2024
Pembrolizumab
Pembrolizumab 200 mg IV infusion given on Day 1 of each 21-day cycle
Carboplatin
Carboplatin AUC 5 mg/mL/minute IV infusion given on Day 1 of each 21-day cycle
Paclitaxel
At investigator's choice, paclitaxel 100 mg/m\^2 IV infusion given on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each 21-day cycle
Hospital Provincial del Centenario ( Site 0304), Rosario
Orange Health Services ( Site 0106), Orange
St Vincents Hospital Melbourne ( Site 0101), Fitzroy
Gold Coast University Hospital ( Site 0103), Southport
The Townsville Hospital ( Site 0105), Douglas
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0262), Mineola
Erie County Medical Center-Head & Neck Surgery and Plastic & Reconstructive Surgery ( Site 0268), Buffalo
UPMC Hillman Cancer Center ( Site 0253), Pittsburgh
Abington Hospital - Asplundh Cancer Center ( Site 0229), Willow Grove
Helen F. Graham Cancer Center & Research Institute ( Site 0214), Newark
Virginia Commonwealth University ( Site 0233), Richmond
Novant Health Forsyth Medical Center ( Site 0266), Winston-Salem
Novant Health Presbyterian ( Site 0261), Charlotte
Charleston Oncology ( Site 0231), Charleston
Baptist MD Anderson Cancer Center ( Site 0215), Jacksonville
Orlando Health, Inc. ( Site 0216), Orlando
Regions Hospital ( Site 0227), Saint Paul
Washington University School of Medicine ( Site 0240), St Louis
Yale-New Haven Hospital-Yale Cancer Center ( Site 0265), New Haven
Centro Medico San Roque ( Site 0302), San Miguel de Tucumán
IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0303), Buenos Aires
Fundación Respirar ( Site 0306), Buenos Aires
Instituto Medico Especializado Alexander Fleming ( Site 0301), Buenos Aires
Centro Regional Integrado de Oncologia ( Site 0403), Fortaleza
CETUS Hospital Dia Oncologia ( Site 0400), Belo Horizonte
Liga Norte Riograndense Contra o Cancer ( Site 0404), Natal
ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0406), Ijuí
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0402), São Paulo
Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0401), São Paulo
A.C. Camargo Cancer Center ( Site 0405), São Paulo
Tom Baker Cancer Center ( Site 0014), Calgary
Dr. H. Bliss Murphy Cancer Centre ( Site 0001), St. John's
Cancer Centre of Southeastern Ontario at Kingston General Hospital ( Site 0004), Kingston
Princess Margaret Cancer Centre ( Site 0005), Toronto
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0003), Sherbrooke
Merck Sharp & Dohme LLC
INDUSTRY